1-(4-pyridinylmethyl)-2,5-dimethylpyrrole | 104439-82-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(4-pyridinylmethyl)-2,5-dimethylpyrrole
• 英文别名: 1--2,5-dimethyl-pyrrol；4-(2,5-dimethyl-pyrrol-1-ylmethyl)-pyridine；4-((2,5-Dimethyl-1H-pyrrol-1-yl)methyl)pyridine；4-[(2,5-dimethylpyrrol-1-yl)methyl]pyridine
• CAS: 104439-82-9
• 化学式: C₁₂H₁₄N₂
• mdl: MFCD01552259
• 分子量: 186.257
• InChiKey: MHFRUOPVRWSGSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-甲氨基吡啶 、 2,5-己二酮 以 乙醇 为溶剂， 反应 10.0h， 生成 1-(4-pyridinylmethyl)-2,5-dimethylpyrrole
  参考文献：
  名称：

  Novel 2,5-Hexanedione Analogues. Substituent-Induced Control of the Protein Cross-Linking Potential and Oxidation Susceptibility of the Resulting Primary Amine-Derived Pyrroles

  摘要：

  The neurotoxic gamma -diketone, 2,5-hexanedione (2,5-HD), induces neurofilamentous swellings at prenodal sites in proximal axons as a consequence of pyrrolation of lysine E-amino groups on neurofilament proteins. However, there is disagreement as to whether pyrrole formation and the associated alteration of noncovalent interactions is sufficient to cause neurofilament accumulation, or whether pyrrole autoxidation and subsequent protein-protein cross-linking is an obligatory event. To investigate gamma -diketones that might form pyrroles inert to autoxidative-induced cross-linking, we synthesized 1,1,1-trifluoro-2,5-hexanedione, 3-(trifluoromethyl)-2,5-hexanedione (3-TFMHD), and two 3-(dialkylaminocarbonyl)-2,5-diketones and assessed their rates of pyrrole formation with amines, the oxidation susceptibility of the resulting pyrroles, and the protein cross-linking potential in vitro, relative to those of 3-methyl-2,5-hexanedione. 1,1,1-Trifluoro-2,5-hexanedione does not form pyrroles, but the three 2,5-HD analogues with an electron-withdrawing 3-substituent all rapidly formed pyrroles that were inert to autoxidation. Although 3-TMFHD nonetheless still induced cross-linking of ribonuclease A, by a nonoxidative mechanism independent of the pyrrole, the two 3-(dialkylaninocarbonyl)-2,5-diketones did not exhibit any protein cross-linking. As these two gamma -diketones possess aqueous-organic partitioning properties similar to those of 2,5-HD, they should serve as useful mechanistic probes in further studies.

  DOI：

  10.1021/tx000169q

文献信息

• ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1529525A1

  公开（公告）日：2005-05-11

  The present invention relates to the use of compounds which enhance the transcription of endothelial nitric oxide synthase (eNOS) for treating stem and progenitor cells in the cell therapy of patients with ischemic heart diseases such as coronary heart disease or ischemic cardiomyopathy. Treatment of such cells which are isolated from bone marrow, for example, with an eNOS transcription enhancer prior to their administration improves their functional activity and ameliorates neovascularization of the heart and cardiac regeneration.

  本发明涉及使用增强内皮型一氧化氮合酶(eNOS)转录的化合物，用于治疗缺血性心脏病患者的干细胞和祖细胞的细胞治疗，例如冠心病或缺血性心肌病。例如，对从骨髓中分离出来的这些细胞进行eNOS转录增强剂的处理，然后再进行其输注，可以提高它们的功能活性并改善心脏的新生血管生成和心脏再生。
• Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
  申请人：Zeiher Andreas

  公开号：US20050101599A1

  公开（公告）日：2005-05-12

  The present invention relates to the use of compounds which enhance the transcription of endothelial nitric oxide synthase (eNOS) for treating stem and progenitor cells in the cell therapy of patients with ischemic heart diseases such as coronary heart disease or ischemic cardiomyopathy. Treatment of such cells which are isolated from bone marrow, for example, with an eNOS transcription enhancer prior to their administration improves their functional activity and ameliorates neovascularization of the heart and cardiac regeneration.

  本发明涉及使用增强内皮型一氧化氮合酶(eNOS)转录的化合物，用于治疗冠心病或缺血性心肌病等缺血性心脏疾病患者的干细胞和祖细胞细胞治疗。例如，对于从骨髓中分离出的这些细胞，在它们被注入前使用eNOS转录增强剂进行治疗，可以改善它们的功能活性，并改善心脏的新生血管生成和心脏再生。
• Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents
  申请人：——

  公开号：US20030008915A1

  公开（公告）日：2003-01-09

  The present invention relates to compounds according to the general formula (I), 1 wherein R 1 -R 4 have the meanings given in the description, A is CH 2 , CHOH or CH—(C 1 -C 3 -alkyl), B, C and D are independently CH 2 or CH—(C 1 -C 3 -alkyl), and R 5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description. These compounds are useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, or restricted memory performance or for a restricted ability to learn, or the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.

  本发明涉及符合一般式（I）的化合物，其中R1-R4具有描述中给出的含义，A为CH2，CHOH或CH-（C1-C3-烷基），B、C和D分别为 或CH-（C1-C3-烷基），R5为芳基或杂芳基，可能被描述中列出的取代基取代。这些化合物可用于制造治疗心血管疾病、稳定或不稳定性心绞痛、冠心病、普林兹梅塔尔心绞痛、急性冠状动脉综合征、心力衰竭、心肌梗死、中风、血栓形成、周围动脉闭塞性疾病、内皮功能障碍、动脉粥样硬化、再狭窄、PTCA后内皮损伤、高血压、原发性高血压、肺动脉高压、继发性高血压、肾血管性高血压、慢性肾小球肾炎、勃起功能障碍、室性心律失常、糖尿病、糖尿病并发症、肾病、视网膜病变、血管生成、支气管哮喘、慢性肾功能衰竭、肝硬化、或受限的记忆表现或受限的学习能力，或降低绝经后妇女或口服避孕药后心血管风险的药物。
• eNOS transcription enhancers for use in the cell therapy of ischemic heart diseases
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP2198861A2

  公开（公告）日：2010-06-23

  The present invention relates to the use of compounds which enhance the transcription of endothelial nitric oxide synthase (eNOS) for treating stem and progenitor cells in the cell therapy of patients with ischemic heart diseases such as coronary heart disease or ischemic cardiomyopathy. Treatment of such cells which are isolated from bone marrow, for example, with an eNOS transcription enhancer prior to their administration improves their functional activity and ameliorates neovascularization of the heart and cardiac regeneration.

  本发明涉及在对冠心病或缺血性心肌病等缺血性心脏病患者进行细胞治疗时，使用能增强内皮一氧化氮合酶（eNOS）转录的化合物来治疗干细胞和祖细胞。例如，用 eNOS 转录增强剂处理从骨髓中分离出来的此类细胞，可提高其功能活性，改善心脏血管新生和心脏再生。
• Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents
  申请人：——

  公开号：US20030022935A1

  公开（公告）日：2003-01-30

  The present invention relates to compounds of general formula (I), 1 wherein R 1 -R 4 have the meanings given in the specification, A is CH2, CHOH or CH-(C 1 -C 3 -alkyl), B and C are independently CH 2 or CH-(C 1 -C 3 -alkyl), and R 5 is an aryl or heteroaryl group optionally substituted by the substituents listed in the specification. The compounds are useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, and restricted memory performance or a restricted ability to learn, or the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.

  本发明涉及通式(I)的化合物、 1 其中 R 1 -R 4 具有说明书中给出的含义，A 是 CH2、CHOH 或 CH-（C 1 -C 3 -烷基），B 和 C 独立地为 CH 2 或 CH-（C 1 -C 3 -烷基），以及 R 5 是芳基或杂芳基，可任选被说明书中列出的取代基取代。糖尿病或糖尿病并发症、肾病或视网膜病变、血管生成、支气管哮喘、慢性肾功能衰竭、肝硬化、骨质疏松症、记忆力受限或学习能力受限，或降低绝经后妇女或服用避孕药后的心血管风险。